Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by American International Group Inc.

American International Group Inc. lowered its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 3.1% in the fourth quarter, HoldingsChannel.com reports. The fund owned 241,898 shares of the biopharmaceutical company’s stock after selling 7,662 shares during the quarter. American International Group Inc.’s holdings in Halozyme Therapeutics were worth $8,941,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Principal Securities Inc. acquired a new stake in Halozyme Therapeutics during the 4th quarter worth about $34,000. First Horizon Advisors Inc. lifted its holdings in shares of Halozyme Therapeutics by 24.5% in the 4th quarter. First Horizon Advisors Inc. now owns 1,491 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 293 shares during the period. Parkside Financial Bank & Trust acquired a new position in shares of Halozyme Therapeutics in the 4th quarter valued at about $64,000. Headlands Technologies LLC lifted its holdings in shares of Halozyme Therapeutics by 1,068.2% in the 4th quarter. Headlands Technologies LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 1,613 shares during the period. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Halozyme Therapeutics by 22.4% in the 4th quarter. Quadrant Capital Group LLC now owns 3,414 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 624 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on HALO. StockNews.com raised Halozyme Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, February 23rd. Wells Fargo & Company boosted their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a report on Friday, June 7th. Benchmark restated a “buy” rating and issued a $50.00 price target on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. Piper Sandler lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and lifted their price target for the company from $48.00 to $51.00 in a research note on Friday, June 7th. Finally, JMP Securities cut their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating for the company in a research note on Wednesday, May 8th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $54.13.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $45.38, for a total transaction of $453,800.00. Following the completion of the sale, the senior vice president now directly owns 168,176 shares in the company, valued at approximately $7,631,826.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. In the last three months, insiders sold 30,000 shares of company stock worth $1,338,800. Corporate insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Price Performance

NASDAQ:HALO opened at $50.27 on Wednesday. Halozyme Therapeutics, Inc. has a 12 month low of $32.83 and a 12 month high of $53.00. The stock has a 50 day moving average of $43.22 and a two-hundred day moving average of $39.82. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The firm has a market cap of $6.40 billion, a P/E ratio of 20.77, a price-to-earnings-growth ratio of 0.50 and a beta of 1.28.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.71 EPS for the quarter, topping the consensus estimate of $0.64 by $0.07. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The company had revenue of $195.88 million during the quarter, compared to analyst estimates of $201.72 million. On average, analysts expect that Halozyme Therapeutics, Inc. will post 3.66 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.